Blake Cameron, MD, MBI

Medical Director for the Digital Strategy Office

Duke University

Blake Cameron is an Associate Professor of Medicine, practicing nephrologist, and physician leader at Duke Health. He serves as Medical Director for the Digital Strategy Office of Duke University Health System, where he provides clinical leadership for the planning and execution of enterprise digital health programs. He additionally leads telehealth and digital access innovation for Private Diagnostic Clinic, the faculty physician practice of Duke Health, and serves on the board of managers for the Duke Connected Care ACO.

He earned his medical degree at Loma Linda University School of Medicine and a Master’s in Clinical Informatics from Oregon Health & Science University. He completed his Internal Medicine residency and Nephrology fellowship training at Duke University Medical Center. In his spare time, he enjoys mountain biking, reading and hiking with his family.

Lana Feng, PhD

Co-Founder and CEO


Lana Feng is the Co-Founder and CEO of Huma.AI. She has led the company from inception to growth phase post series A, providing its generative AI platform to Pharma and life science companies to automate manual data curation and eliminate data bottlenecks in medical affairs, clinical development, RWE, and post-market surveillance.

Dr. Feng spent over 20 years in precision medicine. Dr. Feng, before founding Huma.Al, she came from Novartis Oncology Business Unit where she established international partnerships for their targeted cancer therapeutics programs. She joined Novartis through its acquisition of Genoptix. Dr. Feng built the BioPharma division at Genoptix, where she grew the business from zero to $45M in five years by forging alliances with pharmaceutical companies and providing companion diagnostics development for targeted cancer therapies. The division was instrumental in Genoptix’ acquisition by Novartis for $500M.

Bradford Hirsch, MD, MBA

Head of Product & Implementation


Bradford Hirsch leads product development and implementation at Verily, an Alphabet precision health company. In this role, he oversees the development and delivery of solutions to accelerate clinical research and improve care.

Dr. Hirsch joined Verily through its acquisition of SignalPath in 2021, a clinical trials technology solution, where he served as Co-Founder and CEO. Research sites and sponsors use SignalPath to run more efficient and effective clinical research studies, and under Dr. Hirsch’s leadership, it has been widely adopted by leading health systems.

Prior to SignalPath, he served as Senior Medical Director at Flatiron Health and was on the faculty at Duke University. He is a medical oncologist and has been a principal investigator, ensuring that his approach to reimagining clinical research and care delivery is driven by deep knowledge and experience.

Dr. Hirsch sits on the board of directors for Galvani Bioelectronics, a company developing therapies to treat chronic diseases through implant-based modulation of neural signals, and serves on multiple non profit boards such as the National Outdoor Leadership School, AT&T Performing Arts Center and the Parkland Hospital Foundation. He received his BA from the University of Pennsylvania, and his MD from UT Southwestern and his MBA from Duke University.


David Ridley, PhD

Faculty Director

Duke Health Sector Management

David Ridley, PhD is the Dr. and Mrs. Frank A. Riddick Professor of the Practice of Business. He is also the Faculty Director of Duke’s Health Sector Management. Ridley teaches in the daytime MBA, executive MBA, and Health Analytics programs. He received a PhD in economics from Duke University in 2001.

In his research, Ridley examines innovation and pricing in health care. To encourage development of new treatments for neglected diseases, Ridley (with Jeff Moe and Henry Grabowski) proposed the priority review voucher program which became law in the United States in 2007. Total voucher sales have exceeded one billion dollars. Ridley’s research appears in economics journals (Journal of Public Economics), medical journals (Journal of the American Medical Association), and scientific journals (Nature Reviews Drug Discovery).

Bimal R. Shah, MD, MBA, FACC, FAHA

Chief Operating Officer and Co-Founder


Bimal R. Shah is a nationally recognized cardiologist who was most recently the Chief Operating Officer and Co-Founder of Homeward. Previously, Dr. Shah became the Chief Medical Officer at Teladoc (NYSE: TDOC) after its merger with Livongo Health (NASDAQ: LVGO). In these roles, he oversaw clinical product strategy, content, value and insight analytics, behavioral health strategy, clinical operations, quality and commercial enablement.

Prior to Livongo, he was the Chief Medical Officer for Emerging Technology and Informatics and Service Line Vice President for Life Sciences at Premier Inc., (NASDAQ: PINC) where he led the P&L across all aspects of strategy, sales, marketing, product management, and operations.

Prior to Premier, Dr. Shah served as an Assistant Professor in both the Department of Medicine and Fuqua School of Business at Duke University where he led numerous research programs in the areas of health services research, implementation science, clinical trials, and registry analyses as well as an administrative role as the Director of Quality for the Department of Medicine.

Dr. Shah graduated from the University of North Carolina – Chapel Hill with highest honors and earned both a MD and MBA from Duke University. He completed his residency in Internal Medicine at Stanford University before finishing a general cardiology fellowship at Duke University.

He remains on faculty at Duke University and serves on the Board of Directors for Floreo and as a member of the Board of Visitors at the Duke University School of Nursing. He previously served on the Board of Visitors at the University of North Carolina – Chapel Hill.